Highbridge Capital Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Highbridge Capital Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,908,157	Closed	-$18.9M	–	711
2021 Q4	$18.9M	Buy	1,908,157 +115,776	+6%	+$1.15M	0.41%	59
2021 Q3	$17.7M	Buy	1,792,381 +705,357	+65%	+$6.91M	0.47%	68
2021 Q2	$10.7M	Buy	1,087,024 +464,694	+75%	+$4.53M	0.3%	102
2021 Q1	$6.03M	Buy	+622,330	New	+$6.11M	0.24%	93

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return

CGC

Continental Grain Company New York $448M AUM 6.81% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCMH

Oxbow Capital Management (HK) Hong Kong $355M AUM 567.47% 1-Year Est. Return

Highbridge Capital Management's GRNA Position: Q1 2022 in Review

Highbridge Capital Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 1,908,157 shares — an estimated $18.9M sold.

Highbridge Capital Management first reported a position in GRNA in Q1 2021 and held it in 4 quarters. The position peaked at $18.9M in Q4 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

Highbridge Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
Highbridge Capital Management sold 1,908,157 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $18.9M.
Highbridge Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2021 and held it in 4 quarters.
Highbridge Capital Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $18.9M in Q4 2021.
39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on Highbridge Capital Management's 13F filing for Q1 2022, filed 11 May 2022.